Aviragen Therapeutics (AVIR) Tops Q1 EPS by 2c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q1 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $570 thousand.

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• China semiconductor equipment imports grow 9% in July, Barclays comments
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance